---
layout: default
title: Ropivacaine
parent: 僅模型預測 (L5)
nav_order: 875
evidence_level: L5
indication_count: 10
---

# Ropivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropivacaine: From Regional Anesthesia to Migraine Disorder

## One-Sentence Summary

> Ropivacaine is an amide-type long-acting local anesthetic, clinically established for regional nerve blocks and infiltration analgesia.
> The TxGNN model predicts it may be effective for **Migraine Disorder** (via sympathetic/sensory ganglion blockade),
> with **4 clinical trials** and **6 publications** currently supporting this direction, though most evidence targets related ganglion-block procedures rather than ropivacaine specifically.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in the Singapore regulatory record (drug not marketed locally); clinically established as an amide-type local anesthetic for regional/nerve block anesthesia |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L3 (observational studies, no large RCT specific to ropivacaine for migraine) |
| Singapore Market Status | 未上市 (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information, Ropivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels, producing reversible interruption of nerve conduction. Its efficacy in regional nerve block anesthesia is well established in clinical practice, and mechanistically this sodium-channel blockade may extend to interrupting pain-signal transmission in migraine.

The link between the original use (nerve/ganglion blockade for regional anesthesia) and the predicted new indication (migraine) rests on shared neuroanatomical targets: sphenopalatine ganglion, stellate ganglion, and trigeminal trigger-point injections are all interventional techniques that use local anesthetics — including ropivacaine — to interrupt the trigeminovascular and sympathetic pathways implicated in migraine pathophysiology. This is a procedural (interventional pain management) application rather than a systemic pharmacological indication.

The strongest single piece of direct evidence is NCT00680823, a completed pediatric ED trial (n=150) using paraspinal intramuscular ropivacaine injection specifically for headache — the only sizeable study using ropivacaine itself as the primary intervention. Other trials and literature involve ganglion blocks (sphenopalatine, stellate) where the anesthetic agent is not always confirmed as ropivacaine, which weakens the drug-specific evidence base even though the procedural rationale is sound.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT00680823](https://clinicaltrials.gov/study/NCT00680823) | N/A | Completed | 150 | Paraspinal intramuscular ropivacaine injection evaluated as treatment for headache in a pediatric ED setting — the only trial using ropivacaine as the direct intervention |
| [NCT03666663](https://clinicaltrials.gov/study/NCT03666663) | Phase 4 | Completed | 10 | RCT of sphenopalatine ganglion block with nasal anesthetics vs. placebo for migraine prevention; small sample, anesthetic agent not confirmed as ropivacaine |
| [NCT05301387](https://clinicaltrials.gov/study/NCT05301387) | N/A | Completed | 38 | Sphenopalatine ganglion block vs. placebo for postdural puncture headache (related but distinct from migraine) |
| [NCT06470581](https://clinicaltrials.gov/study/NCT06470581) | N/A | Not yet recruiting | 78 | Thoracic sympathetic ganglion block trial; primary intervention is botulinum toxin A, not ropivacaine — low direct relevance |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [24284858](https://pubmed.ncbi.nlm.nih.gov/24284858/) | 2013 | Review | Pain Physician | Reviews transnasal sphenopalatine ganglion block techniques for headache and facial pain |
| [35331152](https://pubmed.ncbi.nlm.nih.gov/35331152/) | 2022 | Cohort | BMC Anesthesiology | Ultrasound-guided stellate ganglion block observed to relieve migraine pain and improve quality of life |
| [17244105](https://pubmed.ncbi.nlm.nih.gov/17244105/) | 2007 | Cohort | Pain Medicine | Ropivacaine trigger-point injections evaluated over 12 weeks for prophylactic management of severe migraine |
| [30043973](https://pubmed.ncbi.nlm.nih.gov/30043973/) | 2019 | Cohort | Headache | Sphenopalatine ganglion block reduces self-reported pain in status migrainosus |
| [19145569](https://pubmed.ncbi.nlm.nih.gov/19145569/) | 2009 | Case Report | Revista de Neurología | Horner's syndrome complication following epidural analgesia — safety signal, not efficacy evidence |
| [17058040](https://pubmed.ncbi.nlm.nih.gov/17058040/) | 2006 | Case Report | J Headache Pain | Migraine headache reported as a rare complication after cervicothoracic block |

---

## Singapore Market Information

Ropivacaine currently has **no authorization records** in the Singapore regulatory dataset (0 licenses, market status: Not Marketed). No local product/label data is available for review.

---

## Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-interaction data are not currently available in this evidence pack (flagged as a Blocking data gap — TFDA/HSA label warnings and contraindications must be retrieved before any safety evaluation can proceed).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The mechanistic rationale (sodium-channel blockade interrupting trigeminovascular/sympathetic pain pathways) is plausible and supported by L3-level observational evidence, but the only trial using ropivacaine as the direct study intervention is a pediatric ED study, not a migraine-specific RCT. Critically, safety data (warnings/contraindications) is a Blocking gap and the drug is not marketed in Singapore, so a safety evaluation cannot begin.

**To proceed, the following is needed:**
- TFDA/HSA package insert warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- A trial or study using ropivacaine specifically (not other anesthetics or botulinum toxin) as the intervention for migraine, ideally RCT-level
- Route compatibility assessment — required administration route (ganglion/trigger-point injection) vs. available formulations, currently unassessed ("pending")
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

